FINWIRES · TerminalLIVE
FINWIRES

Santana Minerals Advances South Island Gold Project on Approvals Progress, Exploration Upside

By

Santana Minerals (ASX:SMI, NZE:SMI) reported steady progress across permitting, financing, and exploration at its Bendigo-Ophir Gold Project in New Zealand's South Island, highlighted by advancing fast-track approvals (FTA), a AU$130 million capital raise, and continued high-grade drilling success at the Rise and Shine deposit, according to a Tuesday filing with the Australian and New Zealand bourses.

The company said the FTA process for Bendigo-Ophir remains a priority, with a consent decision set for Oct. 29 and engagement with the FTA expert panel already underway.

Key infrastructure milestones include a finalized road access agreement with the Central Otago District Council and the creation of a NZ$1.3 million annual community fund.

Operational readiness is advancing through key mining fleet agreements with Komatsu, alongside exploration success at the Rise and Shine deposit, where mineralization has been extended to over 2.2 kilometers with strong high-grade intercepts.

The company completed a AU$130 million capital raising alongside a AU$4.1 million share purchase plan, strengthening funding for its predominantly debt-funded development plan, and closed the third quarter with a net cash balance of AU$184 million after payables.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA